NPM1 and acute myeloid leukemia: CAR-CIML NK cells targeting a neoepitope generated in nucleophosmin-1 (NPM1)-mutated acute myeloid lymphoma (AML) displayed potent activity, improving AML outcomes in xenograft models [130].